G6PD promotes cell proliferation and dexamethasone resistance in multiple myeloma via increasing anti-oxidant production and activating Wnt/β-catenin pathway
Abstract Background Glucose-6-phosphate dehydrogenase (G6PD) as the rate-limiting enzyme in the pentose phosphate pathway (PPP) is well-established as an aberrantly expressed protein in numerous clinical diseases; however, its role in cancer, specifically in multiple myeloma (MM) remains elusive. Me...
Main Authors: | Rui Li, Mengying Ke, Mingming Qi, Zhenru Han, Yuhao Cao, Zhendong Deng, Jinjun Qian, Ye Yang, Chunyan Gu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2022-10-01
|
Series: | Experimental Hematology & Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40164-022-00326-6 |
Similar Items
-
Dexamethasone and Dexamethasone Phosphate: Effect on DMPC Membrane Models
by: Candelaria Ines Cámara, et al.
Published: (2023-03-01) -
Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
by: Laura Rosiñol, et al.
Published: (2023-11-01) -
Dexamethasone monotherapy in a frail and chemotherapy-ineligible patient with end-stage multiple myeloma: a case report and literature review
by: O. Oey, et al.
Published: (2022-11-01) -
Combination of cyclophosphamide, etoposide, carboplatin and dexamethasone as a salvage regimen for refractory multiple myeloma patients: a comparison with a historical control group
by: Reza Safaee, et al.
Published: (2012-07-01) -
Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma
by: María Victoria Mateos, et al.
Published: (2023-02-01)